The German group posted a recovery in its pharma arm after strong demand for key drugs allowed it to offset market pressures at its agricultural and consumer-health divisions. Bayer has revised its full-year earnings outlook upward, reflecting improved performance in its pharmaceutical segment. The recovery comes as the company navigates challenging market conditions in its other business units.
Strong demand for key medications has driven the positive shift in the company's financial trajectory.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing